{
    "Rank": 441,
    "Study": {
        "ProtocolSection": {
            "IdentificationModule": {
                "NCTId": "NCT01441115",
                "OrgStudyIdInfo": {
                    "OrgStudyId": "110248"
                },
                "SecondaryIdInfoList": {
                    "SecondaryIdInfo": [
                        {
                            "SecondaryId": "11-C-0248"
                        }
                    ]
                },
                "Organization": {
                    "OrgFullName": "National Institutes of Health Clinical Center (CC)",
                    "OrgClass": "NIH"
                },
                "BriefTitle": "ECI301 and Radiation for Advanced or Metastatic Cancer",
                "OfficialTitle": "Phase I Trial of ECI301 in Combination With Radiation in Patients With Advanced or Metastatic Cancer"
            },
            "StatusModule": {
                "StatusVerifiedDate": "November 2021",
                "OverallStatus": "Terminated",
                "WhyStopped": "A trial using ECI301 & radiation was initiated in Japan in 2012. This tested the primary endpoint in a duplicate trial, thus the study was closed.",
                "ExpandedAccessInfo": {
                    "HasExpandedAccess": "No"
                },
                "StartDateStruct": {
                    "StartDate": "September 6, 2011",
                    "StartDateType": "Actual"
                },
                "PrimaryCompletionDateStruct": {
                    "PrimaryCompletionDate": "April 24, 2013",
                    "PrimaryCompletionDateType": "Actual"
                },
                "CompletionDateStruct": {
                    "CompletionDate": "April 24, 2013",
                    "CompletionDateType": "Actual"
                },
                "StudyFirstSubmitDate": "September 24, 2011",
                "StudyFirstSubmitQCDate": "September 24, 2011",
                "StudyFirstPostDateStruct": {
                    "StudyFirstPostDate": "September 27, 2011",
                    "StudyFirstPostDateType": "Estimate"
                },
                "ResultsFirstSubmitDate": "November 3, 2021",
                "ResultsFirstSubmitQCDate": "November 30, 2021",
                "ResultsFirstPostDateStruct": {
                    "ResultsFirstPostDate": "December 28, 2021",
                    "ResultsFirstPostDateType": "Actual"
                },
                "LastUpdateSubmitDate": "November 30, 2021",
                "LastUpdatePostDateStruct": {
                    "LastUpdatePostDate": "December 28, 2021",
                    "LastUpdatePostDateType": "Actual"
                }
            },
            "SponsorCollaboratorsModule": {
                "ResponsibleParty": {
                    "ResponsiblePartyType": "Principal Investigator",
                    "ResponsiblePartyInvestigatorFullName": "Deborah Citrin, M.D.",
                    "ResponsiblePartyInvestigatorTitle": "Principal Investigator",
                    "ResponsiblePartyInvestigatorAffiliation": "National Cancer Institute (NCI)"
                },
                "LeadSponsor": {
                    "LeadSponsorName": "National Cancer Institute (NCI)",
                    "LeadSponsorClass": "NIH"
                }
            },
            "OversightModule": {
                "OversightHasDMC": "No",
                "IsFDARegulatedDrug": "Yes",
                "IsFDARegulatedDevice": "No"
            },
            "DescriptionModule": {
                "BriefSummary": "Background:\n\n- ECI301 is a drug that may help make cancer cells more visible to the immune system after radiation. The drug may also help the immune system destroy the cancer at sites that have not received radiation therapy. Researchers want to study ECI301 in people with advanced cancer or cancer that has spread in the body (metastatic).\n\nObjectives:\n\n- To test ECI301 with radiation therapy for advanced or metastatic cancer.\n\nEligibility:\n\n- People at least 18 years of age with either metastatic or advanced cancer that may benefit from radiation therapy.\n\nDesign:\n\nParticipants will be screened with a medical history and physical exam. They will also have blood and urine tests, and imaging studies.\nAll participants will have radiation therapy 5 days a week for 2 weeks.\nThey will have different doses of ECI301 to test its safety and effectiveness. ECI301 will be given in a vein during the second week of radiation therapy. Frequent blood tests and imaging studies will monitor the treatment.\nAfter participants have ECI301, tumor samples may be taken from the site that had radiation and another site that did not have radiation.\nFollow-up visits will include blood tests and imaging studies.",
                "DetailedDescription": "Background:\n\nPatients with metastatic or locally advanced cancer frequently require palliative radiotherapy to relieve symptoms; however, progression of disease is frequent in patients with extended survival\nRadiation results in tumor cell death which can result in increased dendritic cell activation and trafficking\nECI301 is a derivative of Macrophage Inflammatory Protein-1 alpha, a 70 amino acid chemokine that is a ligand for C-C chemokine receptor type 1 (CCR1) and C-C chemokine receptor type 5 (CCR5), the chemokine receptors of immature dendritic cells.\nECI301 has been shown to enhance the effect of radiotherapy in animal models.\n\nObjectives:\n\nThe primary objective is to determine the maximum tolerated dose (MTD) of ECI301 delivered in combination with 30 Gray (Gy) of external beam radiation to patients with metastatic or locally advanced cancer.\n\nThe secondary objectives are:\n\nTo describe the safety and tolerability of ECI301 delivered in combination with 30 Gy of external beam radiation to patients with metastatic or locally advanced cancer\n\nTo evaluate the humoral and cellular immune responses by:\n\nMeasurement of circulating precursor dendritic cells before and after the completion of ECI301\nMeasurement of circulating MIP-alpha before and after the completion of ECI301\nAssessment of T-lymphocyte quantitative and qualitative changes by flow cytometry and assays for interferon (IFN-gamma) production\nTo define pharmacologic parameters following the intravenous dose of ECI301\nTo determine if neutralizing anti-EC301 antibodies occur after treatment\nTo describe the response at the radiated site and distant sites after radiation in combination with ECI301\n\nEligibility:\n\nAge >18 years.\nEastern Cooperative Oncology Group (ECOG) performance status <2.\nLife expectancy of greater than 3 months\nHistologically confirmed metastatic or locally advanced cancer for which radiotherapeutic management would be appropriate\nNo recent history of myocardial infarction or unstable angina\n\nDesign:\n\nThis is a Phase I trial to determine the maximum tolerated dose of ECI301 in combination with external beam radiation therapy in patients with locally advanced or metastatic solid tumors.\nPatients will be treated with radiation therapy in a standard manner with ECI301 given daily during radiation. The dose of ECI301 will be escalated over the course of the trial to determine the maximum tolerated dose (MTD of daily ECI301 in combination with radiotherapy.\nWe anticipate that accrual to this trial of 30 patients will take approximately 2 years."
            },
            "ConditionsModule": {
                "ConditionList": {
                    "Condition": [
                        "Cancer",
                        "Neoplasm Metastasis",
                        "Radiation Oncology",
                        "Neoplasm",
                        "Metastasis"
                    ]
                },
                "KeywordList": {
                    "Keyword": [
                        "Metastasis",
                        "Cancer",
                        "Radiation Therapy",
                        "Locally Advanced",
                        "Palliation",
                        "Metastatic Cancer"
                    ]
                }
            },
            "DesignModule": {
                "StudyType": "Interventional",
                "PhaseList": {
                    "Phase": [
                        "Phase 1"
                    ]
                },
                "DesignInfo": {
                    "DesignAllocation": "N/A",
                    "DesignInterventionModel": "Single Group Assignment",
                    "DesignPrimaryPurpose": "Treatment",
                    "DesignMaskingInfo": {
                        "DesignMasking": "None (Open Label)"
                    }
                },
                "EnrollmentInfo": {
                    "EnrollmentCount": "2",
                    "EnrollmentType": "Actual"
                }
            },
            "ArmsInterventionsModule": {
                "ArmGroupList": {
                    "ArmGroup": [
                        {
                            "ArmGroupLabel": "ECI301 Dose level 1 - 25 ug/kg and Radiation for Advanced or Metastatic Cancer",
                            "ArmGroupType": "Experimental",
                            "ArmGroupDescription": "ECI301 Dose level 1 - 25 ug/kg and Radiation for Advanced or Metastatic Cancer",
                            "ArmGroupInterventionList": {
                                "ArmGroupInterventionName": [
                                    "Procedure: Radiation Therapy",
                                    "Drug: ECI301"
                                ]
                            }
                        }
                    ]
                },
                "InterventionList": {
                    "Intervention": [
                        {
                            "InterventionType": "Procedure",
                            "InterventionName": "Radiation Therapy",
                            "InterventionArmGroupLabelList": {
                                "InterventionArmGroupLabel": [
                                    "ECI301 Dose level 1 - 25 ug/kg and Radiation for Advanced or Metastatic Cancer"
                                ]
                            }
                        },
                        {
                            "InterventionType": "Drug",
                            "InterventionName": "ECI301",
                            "InterventionArmGroupLabelList": {
                                "InterventionArmGroupLabel": [
                                    "ECI301 Dose level 1 - 25 ug/kg and Radiation for Advanced or Metastatic Cancer"
                                ]
                            }
                        }
                    ]
                }
            },
            "OutcomesModule": {
                "PrimaryOutcomeList": {
                    "PrimaryOutcome": [
                        {
                            "PrimaryOutcomeMeasure": "Maximum Tolerated Dose (MTD) of ECI301 Delivered in Combination With 30 Gray (Gy) External Beam Radiation to Participants With Metastatic or Locally Advanced Cancer",
                            "PrimaryOutcomeDescription": "MTD is defined as the highest dose level at which no more than 1 of 6 participants experience dose-limiting toxicity (DLT) during treatment or the first three weeks after treatment, and the dose below that at which at least 2 (of \u22646) participants have DLT as a result of the drug. Examples of DLT is any grade 3 or greater non-hematologic toxicity, ang grade 3 neutropenia or thrombocytopenia, any grade 4 anemia, and toxicity requiring a cumulative radiation treatment delay of 4 or more days.",
                            "PrimaryOutcomeTimeFrame": "During treatment or the first three weeks after treatment"
                        }
                    ]
                },
                "SecondaryOutcomeList": {
                    "SecondaryOutcome": [
                        {
                            "SecondaryOutcomeMeasure": "Number of Adverse Events Unrelated, Unlikely, and Possibly Related to ECI301 Delivered in Combination With 30 Gray (Gy) of External Beam Radiation to Participants With Metastatic or Locally Advanced Cancer",
                            "SecondaryOutcomeDescription": "Adverse events were assessed by the Common Terminology Criteria for Adverse Events (CTCAE v4.0) and the Radiation Therapy Oncology Group (RTOG) criteria.",
                            "SecondaryOutcomeTimeFrame": "Date treatment consent signed to date off study, and up to 30 days following the last dose of study drug, approximately 5 months and 25 days."
                        },
                        {
                            "SecondaryOutcomeMeasure": "Humoral and Cellular Immune Responses",
                            "SecondaryOutcomeDescription": "Measurement of circulating precursor dendritic cells, circulating macrophage inflammatory protein-1 alpha (MIP-\u03b1), and assessment of T-lymphocytes will be measured by flow cytometry and assays for type II interferon (IFN\u03b3) production.",
                            "SecondaryOutcomeTimeFrame": "Before and after completion of ECI301"
                        },
                        {
                            "SecondaryOutcomeMeasure": "Pharmacologic Parameters Following the Intravenous Dose of ECI301",
                            "SecondaryOutcomeDescription": "Pharmacologic parameters will be derived using non-compartmental analysis.",
                            "SecondaryOutcomeTimeFrame": "Following the intravenous dose of ECI301"
                        },
                        {
                            "SecondaryOutcomeMeasure": "Number of Participants With Response at the Radiated Site and Distant Site After Radiation in Combination With ECI301",
                            "SecondaryOutcomeDescription": "Response will be measured by the Response Evaluation Criteria in Solid Tumors (RECIST). Complete response is disappearance of all target lesions. Partial response is at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters. Progressive disease is at least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study. The appearance of one or more new lesions is also considered progression. Stable disease is neither sufficient shrinkage to qualify for partial response nor sufficient increase to qualify for progressive disease.",
                            "SecondaryOutcomeTimeFrame": "6 months"
                        }
                    ]
                },
                "OtherOutcomeList": {
                    "OtherOutcome": [
                        {
                            "OtherOutcomeMeasure": "Here is the Number of Participants With Non-Serious Adverse Events Assessed by the Common Terminology Criteria for Adverse Events (CTCAE v4.0)",
                            "OtherOutcomeDescription": "Here is the number of participants with non-serious adverse events assessed by the Common Terminology Criteria for Adverse Events (CTCAE v4.0). A non-serious adverse event is any untoward medical occurrence. A serious adverse event is an adverse event or suspected adverse reaction that results in death, a life-threatening adverse drug experience, hospitalization, disruption of the ability to conduct normal life functions, congenital anomaly/birth defect or important medical events that jeopardize the patient or subject and may require medical or surgical intervention to prevent one of the previous outcomes mentioned.",
                            "OtherOutcomeTimeFrame": "Date treatment consent signed to date off study, and up to 30 days following the last dose of study drug, approximately 5 months and 25 days."
                        },
                        {
                            "OtherOutcomeMeasure": "Number of Participants With a Dose-Limiting Toxicity (DLT)",
                            "OtherOutcomeDescription": "Examples of DLT is any grade 3 or greater non-hematologic toxicity, any grade 3 neutropenia or thrombocytopenia, any grade 4 anemia; nausea, vomiting, diarrhea, tumor pain, or pre-existing hyponatremia, dyselectrolytemia, or orthostatic hypotension that has been optimally treated with anti-emetics, anti-diarrheal, analgesics, or hydration and which persists for over 48 hours despite maximal medical therapy, and toxicity requiring a cumulative radiation treatment delay of 4 or more days.",
                            "OtherOutcomeTimeFrame": "During treatment or the first three weeks after treatment"
                        }
                    ]
                }
            },
            "EligibilityModule": {
                "EligibilityCriteria": "INCLUSION CRITERIA:\n\n2.1.1.1 Age greater than or equal to18 years.\n\n2.1.1.2 Eastern Cooperative Oncology Group (ECOG) performance status less than or equal to 2.\n\n2.1.1.3 Life expectancy of greater than 3 months\n\n2.1.1.4 Histologically confirmed cancer\n\n2.1.1.5 Extracranial metastatic cancer or locally advanced cancer for which palliative radiotherapeutic management would be appropriate (no more than two sites will be treated on this trial)\n\n2.1.1.6 Patients must have measurable or evaluable disease at the site(s) requiring radiation\n\n2.1.1.7 Adequate marrow and organ function defined as\n\nabsolute neutrophil count (ANC) > 1.5 times 10(9)/L,\nplatelet count > 100 times 10(9),\nhemoglobin >9 g/L.\ncreatinine clearance greater than or equal to 60 mL/min/1.73 m(2) for patients with creatinine levels above institutional normal\nserum bilirubin <1.5 times upper limit reference range (ULRR),\nalanine aminotransferase (ALT), aspartate aminotransferase (AST), or\n\nalkaline phosphatase (ALP) <2.5 times the ULRR (<5 times the ULRR in the presence\n\nof liver metastases)\n\n2.1.1.8 Female patients of childbearing potential must either be surgically sterile to prevent pregnancy, be at least 1-year post-menopausal, or have had no menses for 12 months, or agree to use reliable methods of contraception (oral contraceptives, barrier methods, approved contraceptive implant, long-term injectable contraception, copper banded intrauterine device, tubal ligation or abstinence) from time of screening until 4 weeks after discontinuing study treatment. It is not known whether ECI301 has the capacity to induce hepatic enzymes so hormonal contraceptives should be combined with a barrier method of contraception.\n\n2.1.1.9 Male patients must agree to use barrier contraception (i.e. condoms) and refrain from donating sperm from the start of dosing until 16 weeks after discontinuing study treatment. If male patients wish to father children, they should be advised to arrange for freezing of sperm prior to the start of study treatment.\n\nEXCLUSION CRITERIA:\n\n2.1.2.1 Pregnant or lactating females\n\n2.1.2.2 Contraindications to radiotherapy (i.e. prior radiotherapy to the intended treatment site)\n\n2.1.2.3 Untreated or previously treated but progressive intracranial metastases (Patients with previously treated intracranial metastases should have no clinical evidence of progression and be at least 4 weeks from therapy for intracranial metastases)\n\n2.1.2.4 Need for emergent radiotherapy (defined as need for radiotherapy within 24 hours of consultation at the judgment of the treating radiation oncologist)\n\n2.1.2.5 Active treatment with immunosuppressive therapy and subjects taking systemic corticosteroid therapy for any reason including replacement therapy for hypoadrenalism\n\n2.1.2.6 Chemotherapy, radiation therapy, Tamoxifen or investigational therapy during the 4 weeks prior to initiation of protocol therapy\n\n2.1.2.7 History of rheumatoid arthritis, systemic lupus erythematosus, Sjogren's disease, sarcoidosis, vasculitis, polymyositis, temporal arteritis or any other autoimmune disease\n\n2.1.2.8 History of organ transplant\n\n2.1.2.9 Human immunodeficiency virus (HIV), Hepatitis B, or Hepatitis C positivity\n\n2.1.2.10 Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements\n\n2.1.2.11 Use of excluded immune modulating medications within 4 weeks prior to protocol therapy, or requirement for concurrent use.",
                "HealthyVolunteers": "No",
                "Gender": "All",
                "MinimumAge": "18 Years",
                "MaximumAge": "99 Years",
                "StdAgeList": {
                    "StdAge": [
                        "Adult",
                        "Older Adult"
                    ]
                }
            },
            "ContactsLocationsModule": {
                "OverallOfficialList": {
                    "OverallOfficial": [
                        {
                            "OverallOfficialName": "Deborah E Citrin, M.D.",
                            "OverallOfficialAffiliation": "National Cancer Institute (NCI)",
                            "OverallOfficialRole": "Principal Investigator"
                        }
                    ]
                },
                "LocationList": {
                    "Location": [
                        {
                            "LocationFacility": "National Institutes of Health Clinical Center, 9000 Rockville Pike",
                            "LocationCity": "Bethesda",
                            "LocationState": "Maryland",
                            "LocationZip": "20892",
                            "LocationCountry": "United States"
                        }
                    ]
                }
            },
            "ReferencesModule": {
                "ReferenceList": {
                    "Reference": [
                        {
                            "ReferencePMID": "12171547",
                            "ReferenceType": "background",
                            "ReferenceCitation": "Friedman EJ. Immune modulation by ionizing radiation and its implications for cancer immunotherapy. Curr Pharm Des. 2002;8(19):1765-80. doi: 10.2174/1381612023394089."
                        },
                        {
                            "ReferencePMID": "17569618",
                            "ReferenceType": "background",
                            "ReferenceCitation": "Sharp HJ, Wansley EK, Garnett CT, Chakraborty M, Camphausen K, Schlom J, Hodge JW. Synergistic antitumor activity of immune strategies combined with radiation. Front Biosci. 2007 Sep 1;12:4900-10. doi: 10.2741/2436."
                        },
                        {
                            "ReferencePMID": "15203102",
                            "ReferenceType": "background",
                            "ReferenceCitation": "Maurer M, von Stebut E. Macrophage inflammatory protein-1. Int J Biochem Cell Biol. 2004 Oct;36(10):1882-6. doi: 10.1016/j.biocel.2003.10.019."
                        }
                    ]
                }
            },
            "IPDSharingStatementModule": {
                "IPDSharing": "No"
            }
        },
        "ResultsSection": {
            "ParticipantFlowModule": {
                "FlowGroupList": {
                    "FlowGroup": [
                        {
                            "FlowGroupId": "FG000",
                            "FlowGroupTitle": "ECI301 Dose Level 1 - 25 ug/kg and Radiation for Advanced or Metastatic Cancer",
                            "FlowGroupDescription": "ECI301 Dose level 1 - 25 ug/kg and radiation therapy for advanced or metastatic cancer."
                        }
                    ]
                },
                "FlowPeriodList": {
                    "FlowPeriod": [
                        {
                            "FlowPeriodTitle": "Overall Study",
                            "FlowMilestoneList": {
                                "FlowMilestone": [
                                    {
                                        "FlowMilestoneType": "STARTED",
                                        "FlowAchievementList": {
                                            "FlowAchievement": [
                                                {
                                                    "FlowAchievementGroupId": "FG000",
                                                    "FlowAchievementNumSubjects": "2"
                                                }
                                            ]
                                        }
                                    },
                                    {
                                        "FlowMilestoneType": "COMPLETED",
                                        "FlowAchievementList": {
                                            "FlowAchievement": [
                                                {
                                                    "FlowAchievementGroupId": "FG000",
                                                    "FlowAchievementNumSubjects": "1"
                                                }
                                            ]
                                        }
                                    },
                                    {
                                        "FlowMilestoneType": "NOT COMPLETED",
                                        "FlowAchievementList": {
                                            "FlowAchievement": [
                                                {
                                                    "FlowAchievementGroupId": "FG000",
                                                    "FlowAchievementNumSubjects": "1"
                                                }
                                            ]
                                        }
                                    }
                                ]
                            },
                            "FlowDropWithdrawList": {
                                "FlowDropWithdraw": [
                                    {
                                        "FlowDropWithdrawType": "Taken off study - Principal Investigator discretion",
                                        "FlowReasonList": {
                                            "FlowReason": [
                                                {
                                                    "FlowReasonGroupId": "FG000",
                                                    "FlowReasonNumSubjects": "1"
                                                }
                                            ]
                                        }
                                    }
                                ]
                            }
                        }
                    ]
                }
            },
            "BaselineCharacteristicsModule": {
                "BaselineGroupList": {
                    "BaselineGroup": [
                        {
                            "BaselineGroupId": "BG000",
                            "BaselineGroupTitle": "ECI301 Dose Level 1 - 25 ug/kg and Radiation for Advanced or Metastatic Cancer",
                            "BaselineGroupDescription": "ECI301 Dose level 1 - 25 ug/kg and radiation therapy for advanced or metastatic cancer."
                        }
                    ]
                },
                "BaselineDenomList": {
                    "BaselineDenom": [
                        {
                            "BaselineDenomUnits": "Participants",
                            "BaselineDenomCountList": {
                                "BaselineDenomCount": [
                                    {
                                        "BaselineDenomCountGroupId": "BG000",
                                        "BaselineDenomCountValue": "2"
                                    }
                                ]
                            }
                        }
                    ]
                },
                "BaselineMeasureList": {
                    "BaselineMeasure": [
                        {
                            "BaselineMeasureTitle": "Age, Categorical",
                            "BaselineMeasureParamType": "Count of Participants",
                            "BaselineMeasureUnitOfMeasure": "Participants",
                            "BaselineClassList": {
                                "BaselineClass": [
                                    {
                                        "BaselineCategoryList": {
                                            "BaselineCategory": [
                                                {
                                                    "BaselineCategoryTitle": "<=18 years",
                                                    "BaselineMeasurementList": {
                                                        "BaselineMeasurement": [
                                                            {
                                                                "BaselineMeasurementGroupId": "BG000",
                                                                "BaselineMeasurementValue": "0"
                                                            }
                                                        ]
                                                    }
                                                },
                                                {
                                                    "BaselineCategoryTitle": "Between 18 and 65 years",
                                                    "BaselineMeasurementList": {
                                                        "BaselineMeasurement": [
                                                            {
                                                                "BaselineMeasurementGroupId": "BG000",
                                                                "BaselineMeasurementValue": "1"
                                                            }
                                                        ]
                                                    }
                                                },
                                                {
                                                    "BaselineCategoryTitle": ">=65 years",
                                                    "BaselineMeasurementList": {
                                                        "BaselineMeasurement": [
                                                            {
                                                                "BaselineMeasurementGroupId": "BG000",
                                                                "BaselineMeasurementValue": "1"
                                                            }
                                                        ]
                                                    }
                                                }
                                            ]
                                        }
                                    }
                                ]
                            }
                        },
                        {
                            "BaselineMeasureTitle": "Age, Continuous",
                            "BaselineMeasureParamType": "Mean",
                            "BaselineMeasureDispersionType": "Standard Deviation",
                            "BaselineMeasureUnitOfMeasure": "years",
                            "BaselineClassList": {
                                "BaselineClass": [
                                    {
                                        "BaselineCategoryList": {
                                            "BaselineCategory": [
                                                {
                                                    "BaselineMeasurementList": {
                                                        "BaselineMeasurement": [
                                                            {
                                                                "BaselineMeasurementGroupId": "BG000",
                                                                "BaselineMeasurementValue": "60.1",
                                                                "BaselineMeasurementSpread": "9.62"
                                                            }
                                                        ]
                                                    }
                                                }
                                            ]
                                        }
                                    }
                                ]
                            }
                        },
                        {
                            "BaselineMeasureTitle": "Sex: Female, Male",
                            "BaselineMeasureParamType": "Count of Participants",
                            "BaselineMeasureUnitOfMeasure": "Participants",
                            "BaselineClassList": {
                                "BaselineClass": [
                                    {
                                        "BaselineCategoryList": {
                                            "BaselineCategory": [
                                                {
                                                    "BaselineCategoryTitle": "Female",
                                                    "BaselineMeasurementList": {
                                                        "BaselineMeasurement": [
                                                            {
                                                                "BaselineMeasurementGroupId": "BG000",
                                                                "BaselineMeasurementValue": "2"
                                                            }
                                                        ]
                                                    }
                                                },
                                                {
                                                    "BaselineCategoryTitle": "Male",
                                                    "BaselineMeasurementList": {
                                                        "BaselineMeasurement": [
                                                            {
                                                                "BaselineMeasurementGroupId": "BG000",
                                                                "BaselineMeasurementValue": "0"
                                                            }
                                                        ]
                                                    }
                                                }
                                            ]
                                        }
                                    }
                                ]
                            }
                        },
                        {
                            "BaselineMeasureTitle": "Ethnicity (NIH/OMB)",
                            "BaselineMeasureParamType": "Count of Participants",
                            "BaselineMeasureUnitOfMeasure": "Participants",
                            "BaselineClassList": {
                                "BaselineClass": [
                                    {
                                        "BaselineCategoryList": {
                                            "BaselineCategory": [
                                                {
                                                    "BaselineCategoryTitle": "Hispanic or Latino",
                                                    "BaselineMeasurementList": {
                                                        "BaselineMeasurement": [
                                                            {
                                                                "BaselineMeasurementGroupId": "BG000",
                                                                "BaselineMeasurementValue": "0"
                                                            }
                                                        ]
                                                    }
                                                },
                                                {
                                                    "BaselineCategoryTitle": "Not Hispanic or Latino",
                                                    "BaselineMeasurementList": {
                                                        "BaselineMeasurement": [
                                                            {
                                                                "BaselineMeasurementGroupId": "BG000",
                                                                "BaselineMeasurementValue": "2"
                                                            }
                                                        ]
                                                    }
                                                },
                                                {
                                                    "BaselineCategoryTitle": "Unknown or Not Reported",
                                                    "BaselineMeasurementList": {
                                                        "BaselineMeasurement": [
                                                            {
                                                                "BaselineMeasurementGroupId": "BG000",
                                                                "BaselineMeasurementValue": "0"
                                                            }
                                                        ]
                                                    }
                                                }
                                            ]
                                        }
                                    }
                                ]
                            }
                        },
                        {
                            "BaselineMeasureTitle": "Race (NIH/OMB)",
                            "BaselineMeasureParamType": "Count of Participants",
                            "BaselineMeasureUnitOfMeasure": "Participants",
                            "BaselineClassList": {
                                "BaselineClass": [
                                    {
                                        "BaselineCategoryList": {
                                            "BaselineCategory": [
                                                {
                                                    "BaselineCategoryTitle": "American Indian or Alaska Native",
                                                    "BaselineMeasurementList": {
                                                        "BaselineMeasurement": [
                                                            {
                                                                "BaselineMeasurementGroupId": "BG000",
                                                                "BaselineMeasurementValue": "0"
                                                            }
                                                        ]
                                                    }
                                                },
                                                {
                                                    "BaselineCategoryTitle": "Asian",
                                                    "BaselineMeasurementList": {
                                                        "BaselineMeasurement": [
                                                            {
                                                                "BaselineMeasurementGroupId": "BG000",
                                                                "BaselineMeasurementValue": "1"
                                                            }
                                                        ]
                                                    }
                                                },
                                                {
                                                    "BaselineCategoryTitle": "Native Hawaiian or Other Pacific Islander",
                                                    "BaselineMeasurementList": {
                                                        "BaselineMeasurement": [
                                                            {
                                                                "BaselineMeasurementGroupId": "BG000",
                                                                "BaselineMeasurementValue": "0"
                                                            }
                                                        ]
                                                    }
                                                },
                                                {
                                                    "BaselineCategoryTitle": "Black or African American",
                                                    "BaselineMeasurementList": {
                                                        "BaselineMeasurement": [
                                                            {
                                                                "BaselineMeasurementGroupId": "BG000",
                                                                "BaselineMeasurementValue": "0"
                                                            }
                                                        ]
                                                    }
                                                },
                                                {
                                                    "BaselineCategoryTitle": "White",
                                                    "BaselineMeasurementList": {
                                                        "BaselineMeasurement": [
                                                            {
                                                                "BaselineMeasurementGroupId": "BG000",
                                                                "BaselineMeasurementValue": "1"
                                                            }
                                                        ]
                                                    }
                                                },
                                                {
                                                    "BaselineCategoryTitle": "More than one race",
                                                    "BaselineMeasurementList": {
                                                        "BaselineMeasurement": [
                                                            {
                                                                "BaselineMeasurementGroupId": "BG000",
                                                                "BaselineMeasurementValue": "0"
                                                            }
                                                        ]
                                                    }
                                                },
                                                {
                                                    "BaselineCategoryTitle": "Unknown or Not Reported",
                                                    "BaselineMeasurementList": {
                                                        "BaselineMeasurement": [
                                                            {
                                                                "BaselineMeasurementGroupId": "BG000",
                                                                "BaselineMeasurementValue": "0"
                                                            }
                                                        ]
                                                    }
                                                }
                                            ]
                                        }
                                    }
                                ]
                            }
                        },
                        {
                            "BaselineMeasureTitle": "Region of Enrollment",
                            "BaselineMeasureParamType": "Number",
                            "BaselineMeasureUnitOfMeasure": "participants",
                            "BaselineClassList": {
                                "BaselineClass": [
                                    {
                                        "BaselineClassTitle": "United States",
                                        "BaselineCategoryList": {
                                            "BaselineCategory": [
                                                {
                                                    "BaselineMeasurementList": {
                                                        "BaselineMeasurement": [
                                                            {
                                                                "BaselineMeasurementGroupId": "BG000",
                                                                "BaselineMeasurementValue": "2"
                                                            }
                                                        ]
                                                    }
                                                }
                                            ]
                                        }
                                    }
                                ]
                            }
                        }
                    ]
                }
            },
            "OutcomeMeasuresModule": {
                "OutcomeMeasureList": {
                    "OutcomeMeasure": [
                        {
                            "OutcomeMeasureType": "Primary",
                            "OutcomeMeasureTitle": "Maximum Tolerated Dose (MTD) of ECI301 Delivered in Combination With 30 Gray (Gy) External Beam Radiation to Participants With Metastatic or Locally Advanced Cancer",
                            "OutcomeMeasureDescription": "MTD is defined as the highest dose level at which no more than 1 of 6 participants experience dose-limiting toxicity (DLT) during treatment or the first three weeks after treatment, and the dose below that at which at least 2 (of \u22646) participants have DLT as a result of the drug. Examples of DLT is any grade 3 or greater non-hematologic toxicity, ang grade 3 neutropenia or thrombocytopenia, any grade 4 anemia, and toxicity requiring a cumulative radiation treatment delay of 4 or more days.",
                            "OutcomeMeasurePopulationDescription": "This MTD was not found because the trial was terminated early. A trial using ECI301 & radiation was initiated in Japan in 2012. This tested the primary endpoint in a duplicate trial, thus the study was closed. In addition, as specified in the protocol, the number of participants required to complete this trial involves 5 cohorts of 3 to 6 participants.",
                            "OutcomeMeasureReportingStatus": "Posted",
                            "OutcomeMeasureTimeFrame": "During treatment or the first three weeks after treatment",
                            "OutcomeGroupList": {
                                "OutcomeGroup": [
                                    {
                                        "OutcomeGroupId": "OG000",
                                        "OutcomeGroupTitle": "ECI301 Dose Level 1 - 25 ug/kg and Radiation for Advanced or Metastatic Cancer",
                                        "OutcomeGroupDescription": "ECI301 Dose level 1 - 25 ug/kg and radiation therapy for advanced or metastatic cancer."
                                    }
                                ]
                            },
                            "OutcomeDenomList": {
                                "OutcomeDenom": [
                                    {
                                        "OutcomeDenomUnits": "Participants",
                                        "OutcomeDenomCountList": {
                                            "OutcomeDenomCount": [
                                                {
                                                    "OutcomeDenomCountGroupId": "OG000",
                                                    "OutcomeDenomCountValue": "0"
                                                }
                                            ]
                                        }
                                    }
                                ]
                            }
                        },
                        {
                            "OutcomeMeasureType": "Secondary",
                            "OutcomeMeasureTitle": "Number of Adverse Events Unrelated, Unlikely, and Possibly Related to ECI301 Delivered in Combination With 30 Gray (Gy) of External Beam Radiation to Participants With Metastatic or Locally Advanced Cancer",
                            "OutcomeMeasureDescription": "Adverse events were assessed by the Common Terminology Criteria for Adverse Events (CTCAE v4.0) and the Radiation Therapy Oncology Group (RTOG) criteria.",
                            "OutcomeMeasurePopulationDescription": "1/2 participants were analyzed because one participant was taken off study per Principal Investigator discretion and did not receive drug.",
                            "OutcomeMeasureReportingStatus": "Posted",
                            "OutcomeMeasureParamType": "Number",
                            "OutcomeMeasureUnitOfMeasure": "Adverse events",
                            "OutcomeMeasureTimeFrame": "Date treatment consent signed to date off study, and up to 30 days following the last dose of study drug, approximately 5 months and 25 days.",
                            "OutcomeGroupList": {
                                "OutcomeGroup": [
                                    {
                                        "OutcomeGroupId": "OG000",
                                        "OutcomeGroupTitle": "Unrelated",
                                        "OutcomeGroupDescription": "ECI301 Dose level 1 - 25 ug/kg and radiation therapy for advanced or metastatic cancer."
                                    },
                                    {
                                        "OutcomeGroupId": "OG001",
                                        "OutcomeGroupTitle": "Unlikely Related",
                                        "OutcomeGroupDescription": "ECI301 Dose level 1 - 25 ug/kg and radiation therapy for advanced or metastatic cancer."
                                    },
                                    {
                                        "OutcomeGroupId": "OG002",
                                        "OutcomeGroupTitle": "Possibly Related",
                                        "OutcomeGroupDescription": "ECI301 Dose level 1 - 25 ug/kg and radiation therapy for advanced or metastatic cancer."
                                    }
                                ]
                            },
                            "OutcomeDenomList": {
                                "OutcomeDenom": [
                                    {
                                        "OutcomeDenomUnits": "Participants",
                                        "OutcomeDenomCountList": {
                                            "OutcomeDenomCount": [
                                                {
                                                    "OutcomeDenomCountGroupId": "OG000",
                                                    "OutcomeDenomCountValue": "1"
                                                },
                                                {
                                                    "OutcomeDenomCountGroupId": "OG001",
                                                    "OutcomeDenomCountValue": "1"
                                                },
                                                {
                                                    "OutcomeDenomCountGroupId": "OG002",
                                                    "OutcomeDenomCountValue": "1"
                                                }
                                            ]
                                        }
                                    }
                                ]
                            },
                            "OutcomeClassList": {
                                "OutcomeClass": [
                                    {
                                        "OutcomeClassTitle": "Alanine aminotransferase increased",
                                        "OutcomeCategoryList": {
                                            "OutcomeCategory": [
                                                {
                                                    "OutcomeMeasurementList": {
                                                        "OutcomeMeasurement": [
                                                            {
                                                                "OutcomeMeasurementGroupId": "OG000",
                                                                "OutcomeMeasurementValue": "0"
                                                            },
                                                            {
                                                                "OutcomeMeasurementGroupId": "OG001",
                                                                "OutcomeMeasurementValue": "1"
                                                            },
                                                            {
                                                                "OutcomeMeasurementGroupId": "OG002",
                                                                "OutcomeMeasurementValue": "0"
                                                            }
                                                        ]
                                                    }
                                                }
                                            ]
                                        }
                                    },
                                    {
                                        "OutcomeClassTitle": "Anemia",
                                        "OutcomeCategoryList": {
                                            "OutcomeCategory": [
                                                {
                                                    "OutcomeMeasurementList": {
                                                        "OutcomeMeasurement": [
                                                            {
                                                                "OutcomeMeasurementGroupId": "OG000",
                                                                "OutcomeMeasurementValue": "4"
                                                            },
                                                            {
                                                                "OutcomeMeasurementGroupId": "OG001",
                                                                "OutcomeMeasurementValue": "0"
                                                            },
                                                            {
                                                                "OutcomeMeasurementGroupId": "OG002",
                                                                "OutcomeMeasurementValue": "0"
                                                            }
                                                        ]
                                                    }
                                                }
                                            ]
                                        }
                                    },
                                    {
                                        "OutcomeClassTitle": "Aspartate aminotransferase increased",
                                        "OutcomeCategoryList": {
                                            "OutcomeCategory": [
                                                {
                                                    "OutcomeMeasurementList": {
                                                        "OutcomeMeasurement": [
                                                            {
                                                                "OutcomeMeasurementGroupId": "OG000",
                                                                "OutcomeMeasurementValue": "0"
                                                            },
                                                            {
                                                                "OutcomeMeasurementGroupId": "OG001",
                                                                "OutcomeMeasurementValue": "1"
                                                            },
                                                            {
                                                                "OutcomeMeasurementGroupId": "OG002",
                                                                "OutcomeMeasurementValue": "0"
                                                            }
                                                        ]
                                                    }
                                                }
                                            ]
                                        }
                                    },
                                    {
                                        "OutcomeClassTitle": "Edema limbs",
                                        "OutcomeCategoryList": {
                                            "OutcomeCategory": [
                                                {
                                                    "OutcomeMeasurementList": {
                                                        "OutcomeMeasurement": [
                                                            {
                                                                "OutcomeMeasurementGroupId": "OG000",
                                                                "OutcomeMeasurementValue": "1"
                                                            },
                                                            {
                                                                "OutcomeMeasurementGroupId": "OG001",
                                                                "OutcomeMeasurementValue": "0"
                                                            },
                                                            {
                                                                "OutcomeMeasurementGroupId": "OG002",
                                                                "OutcomeMeasurementValue": "0"
                                                            }
                                                        ]
                                                    }
                                                }
                                            ]
                                        }
                                    },
                                    {
                                        "OutcomeClassTitle": "Erythema multiforme",
                                        "OutcomeCategoryList": {
                                            "OutcomeCategory": [
                                                {
                                                    "OutcomeMeasurementList": {
                                                        "OutcomeMeasurement": [
                                                            {
                                                                "OutcomeMeasurementGroupId": "OG000",
                                                                "OutcomeMeasurementValue": "0"
                                                            },
                                                            {
                                                                "OutcomeMeasurementGroupId": "OG001",
                                                                "OutcomeMeasurementValue": "0"
                                                            },
                                                            {
                                                                "OutcomeMeasurementGroupId": "OG002",
                                                                "OutcomeMeasurementValue": "1"
                                                            }
                                                        ]
                                                    }
                                                }
                                            ]
                                        }
                                    },
                                    {
                                        "OutcomeClassTitle": "Gastritis",
                                        "OutcomeCategoryList": {
                                            "OutcomeCategory": [
                                                {
                                                    "OutcomeMeasurementList": {
                                                        "OutcomeMeasurement": [
                                                            {
                                                                "OutcomeMeasurementGroupId": "OG000",
                                                                "OutcomeMeasurementValue": "0"
                                                            },
                                                            {
                                                                "OutcomeMeasurementGroupId": "OG001",
                                                                "OutcomeMeasurementValue": "1"
                                                            },
                                                            {
                                                                "OutcomeMeasurementGroupId": "OG002",
                                                                "OutcomeMeasurementValue": "0"
                                                            }
                                                        ]
                                                    }
                                                }
                                            ]
                                        }
                                    },
                                    {
                                        "OutcomeClassTitle": "Headache",
                                        "OutcomeCategoryList": {
                                            "OutcomeCategory": [
                                                {
                                                    "OutcomeMeasurementList": {
                                                        "OutcomeMeasurement": [
                                                            {
                                                                "OutcomeMeasurementGroupId": "OG000",
                                                                "OutcomeMeasurementValue": "1"
                                                            },
                                                            {
                                                                "OutcomeMeasurementGroupId": "OG001",
                                                                "OutcomeMeasurementValue": "0"
                                                            },
                                                            {
                                                                "OutcomeMeasurementGroupId": "OG002",
                                                                "OutcomeMeasurementValue": "0"
                                                            }
                                                        ]
                                                    }
                                                }
                                            ]
                                        }
                                    },
                                    {
                                        "OutcomeClassTitle": "Hyperkalemia",
                                        "OutcomeCategoryList": {
                                            "OutcomeCategory": [
                                                {
                                                    "OutcomeMeasurementList": {
                                                        "OutcomeMeasurement": [
                                                            {
                                                                "OutcomeMeasurementGroupId": "OG000",
                                                                "OutcomeMeasurementValue": "0"
                                                            },
                                                            {
                                                                "OutcomeMeasurementGroupId": "OG001",
                                                                "OutcomeMeasurementValue": "1"
                                                            },
                                                            {
                                                                "OutcomeMeasurementGroupId": "OG002",
                                                                "OutcomeMeasurementValue": "0"
                                                            }
                                                        ]
                                                    }
                                                }
                                            ]
                                        }
                                    },
                                    {
                                        "OutcomeClassTitle": "Lymphocyte count decreased",
                                        "OutcomeCategoryList": {
                                            "OutcomeCategory": [
                                                {
                                                    "OutcomeMeasurementList": {
                                                        "OutcomeMeasurement": [
                                                            {
                                                                "OutcomeMeasurementGroupId": "OG000",
                                                                "OutcomeMeasurementValue": "1"
                                                            },
                                                            {
                                                                "OutcomeMeasurementGroupId": "OG001",
                                                                "OutcomeMeasurementValue": "0"
                                                            },
                                                            {
                                                                "OutcomeMeasurementGroupId": "OG002",
                                                                "OutcomeMeasurementValue": "0"
                                                            }
                                                        ]
                                                    }
                                                }
                                            ]
                                        }
                                    },
                                    {
                                        "OutcomeClassTitle": "Pain in extremity",
                                        "OutcomeCategoryList": {
                                            "OutcomeCategory": [
                                                {
                                                    "OutcomeMeasurementList": {
                                                        "OutcomeMeasurement": [
                                                            {
                                                                "OutcomeMeasurementGroupId": "OG000",
                                                                "OutcomeMeasurementValue": "1"
                                                            },
                                                            {
                                                                "OutcomeMeasurementGroupId": "OG001",
                                                                "OutcomeMeasurementValue": "0"
                                                            },
                                                            {
                                                                "OutcomeMeasurementGroupId": "OG002",
                                                                "OutcomeMeasurementValue": "0"
                                                            }
                                                        ]
                                                    }
                                                }
                                            ]
                                        }
                                    },
                                    {
                                        "OutcomeClassTitle": "Urinary tract infection",
                                        "OutcomeCategoryList": {
                                            "OutcomeCategory": [
                                                {
                                                    "OutcomeMeasurementList": {
                                                        "OutcomeMeasurement": [
                                                            {
                                                                "OutcomeMeasurementGroupId": "OG000",
                                                                "OutcomeMeasurementValue": "0"
                                                            },
                                                            {
                                                                "OutcomeMeasurementGroupId": "OG001",
                                                                "OutcomeMeasurementValue": "0"
                                                            },
                                                            {
                                                                "OutcomeMeasurementGroupId": "OG002",
                                                                "OutcomeMeasurementValue": "1"
                                                            }
                                                        ]
                                                    }
                                                }
                                            ]
                                        }
                                    }
                                ]
                            }
                        },
                        {
                            "OutcomeMeasureType": "Secondary",
                            "OutcomeMeasureTitle": "Humoral and Cellular Immune Responses",
                            "OutcomeMeasureDescription": "Measurement of circulating precursor dendritic cells, circulating macrophage inflammatory protein-1 alpha (MIP-\u03b1), and assessment of T-lymphocytes will be measured by flow cytometry and assays for type II interferon (IFN\u03b3) production.",
                            "OutcomeMeasurePopulationDescription": "This outcome measure was not done because the trial was terminated early. A trial using ECI301 & radiation was initiated in Japan in 2012. This tested the primary endpoint in a duplicate trial, thus the study was closed. In addition, as specified in the protocol, the number of participants required to complete this trial involves 5 cohorts of 3 to 6 participants.",
                            "OutcomeMeasureReportingStatus": "Posted",
                            "OutcomeMeasureTimeFrame": "Before and after completion of ECI301",
                            "OutcomeGroupList": {
                                "OutcomeGroup": [
                                    {
                                        "OutcomeGroupId": "OG000",
                                        "OutcomeGroupTitle": "ECI301 Dose Level 1 - 25 ug/kg and Radiation for Advanced or Metastatic Cancer",
                                        "OutcomeGroupDescription": "ECI301 Dose level 1 - 25 ug/kg and radiation therapy for advanced or metastatic cancer."
                                    }
                                ]
                            },
                            "OutcomeDenomList": {
                                "OutcomeDenom": [
                                    {
                                        "OutcomeDenomUnits": "Participants",
                                        "OutcomeDenomCountList": {
                                            "OutcomeDenomCount": [
                                                {
                                                    "OutcomeDenomCountGroupId": "OG000",
                                                    "OutcomeDenomCountValue": "0"
                                                }
                                            ]
                                        }
                                    }
                                ]
                            }
                        },
                        {
                            "OutcomeMeasureType": "Secondary",
                            "OutcomeMeasureTitle": "Pharmacologic Parameters Following the Intravenous Dose of ECI301",
                            "OutcomeMeasureDescription": "Pharmacologic parameters will be derived using non-compartmental analysis.",
                            "OutcomeMeasurePopulationDescription": "This outcome measure was not done because the trial was terminated early. A trial using ECI301 & radiation was initiated in Japan in 2012. This tested the primary endpoint in a duplicate trial, thus the study was closed. In addition, as specified in the protocol, the number of participants required to complete this trial involves 5 cohorts of 3 to 6 participants.",
                            "OutcomeMeasureReportingStatus": "Posted",
                            "OutcomeMeasureTimeFrame": "Following the intravenous dose of ECI301",
                            "OutcomeGroupList": {
                                "OutcomeGroup": [
                                    {
                                        "OutcomeGroupId": "OG000",
                                        "OutcomeGroupTitle": "ECI301 Dose Level 1 - 25 ug/kg and Radiation for Advanced or Metastatic Cancer",
                                        "OutcomeGroupDescription": "ECI301 Dose level 1 - 25 ug/kg and radiation therapy for advanced or metastatic cancer."
                                    }
                                ]
                            },
                            "OutcomeDenomList": {
                                "OutcomeDenom": [
                                    {
                                        "OutcomeDenomUnits": "Participants",
                                        "OutcomeDenomCountList": {
                                            "OutcomeDenomCount": [
                                                {
                                                    "OutcomeDenomCountGroupId": "OG000",
                                                    "OutcomeDenomCountValue": "0"
                                                }
                                            ]
                                        }
                                    }
                                ]
                            }
                        },
                        {
                            "OutcomeMeasureType": "Secondary",
                            "OutcomeMeasureTitle": "Number of Participants With Response at the Radiated Site and Distant Site After Radiation in Combination With ECI301",
                            "OutcomeMeasureDescription": "Response will be measured by the Response Evaluation Criteria in Solid Tumors (RECIST). Complete response is disappearance of all target lesions. Partial response is at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters. Progressive disease is at least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study. The appearance of one or more new lesions is also considered progression. Stable disease is neither sufficient shrinkage to qualify for partial response nor sufficient increase to qualify for progressive disease.",
                            "OutcomeMeasurePopulationDescription": "1/2 participants were analyzed because one participant was taken off study per Principal Investigator discretion and did not receive drug.",
                            "OutcomeMeasureReportingStatus": "Posted",
                            "OutcomeMeasureParamType": "Count of Participants",
                            "OutcomeMeasureUnitOfMeasure": "Participants",
                            "OutcomeMeasureTimeFrame": "6 months",
                            "OutcomeGroupList": {
                                "OutcomeGroup": [
                                    {
                                        "OutcomeGroupId": "OG000",
                                        "OutcomeGroupTitle": "ECI301 Dose Level 1 - 25 ug/kg and Radiation for Advanced or Metastatic Cancer",
                                        "OutcomeGroupDescription": "ECI301 Dose level 1 - 25 ug/kg and radiation therapy for advanced or metastatic cancer."
                                    }
                                ]
                            },
                            "OutcomeDenomList": {
                                "OutcomeDenom": [
                                    {
                                        "OutcomeDenomUnits": "Participants",
                                        "OutcomeDenomCountList": {
                                            "OutcomeDenomCount": [
                                                {
                                                    "OutcomeDenomCountGroupId": "OG000",
                                                    "OutcomeDenomCountValue": "1"
                                                }
                                            ]
                                        }
                                    }
                                ]
                            },
                            "OutcomeClassList": {
                                "OutcomeClass": [
                                    {
                                        "OutcomeClassTitle": "Complete Response",
                                        "OutcomeCategoryList": {
                                            "OutcomeCategory": [
                                                {
                                                    "OutcomeMeasurementList": {
                                                        "OutcomeMeasurement": [
                                                            {
                                                                "OutcomeMeasurementGroupId": "OG000",
                                                                "OutcomeMeasurementValue": "0"
                                                            }
                                                        ]
                                                    }
                                                }
                                            ]
                                        }
                                    },
                                    {
                                        "OutcomeClassTitle": "Partial Response",
                                        "OutcomeCategoryList": {
                                            "OutcomeCategory": [
                                                {
                                                    "OutcomeMeasurementList": {
                                                        "OutcomeMeasurement": [
                                                            {
                                                                "OutcomeMeasurementGroupId": "OG000",
                                                                "OutcomeMeasurementValue": "0"
                                                            }
                                                        ]
                                                    }
                                                }
                                            ]
                                        }
                                    },
                                    {
                                        "OutcomeClassTitle": "Stable Disease",
                                        "OutcomeCategoryList": {
                                            "OutcomeCategory": [
                                                {
                                                    "OutcomeMeasurementList": {
                                                        "OutcomeMeasurement": [
                                                            {
                                                                "OutcomeMeasurementGroupId": "OG000",
                                                                "OutcomeMeasurementValue": "1"
                                                            }
                                                        ]
                                                    }
                                                }
                                            ]
                                        }
                                    },
                                    {
                                        "OutcomeClassTitle": "Progressive Disease",
                                        "OutcomeCategoryList": {
                                            "OutcomeCategory": [
                                                {
                                                    "OutcomeMeasurementList": {
                                                        "OutcomeMeasurement": [
                                                            {
                                                                "OutcomeMeasurementGroupId": "OG000",
                                                                "OutcomeMeasurementValue": "0"
                                                            }
                                                        ]
                                                    }
                                                }
                                            ]
                                        }
                                    }
                                ]
                            }
                        },
                        {
                            "OutcomeMeasureType": "Other Pre-specified",
                            "OutcomeMeasureTitle": "Here is the Number of Participants With Non-Serious Adverse Events Assessed by the Common Terminology Criteria for Adverse Events (CTCAE v4.0)",
                            "OutcomeMeasureDescription": "Here is the number of participants with non-serious adverse events assessed by the Common Terminology Criteria for Adverse Events (CTCAE v4.0). A non-serious adverse event is any untoward medical occurrence. A serious adverse event is an adverse event or suspected adverse reaction that results in death, a life-threatening adverse drug experience, hospitalization, disruption of the ability to conduct normal life functions, congenital anomaly/birth defect or important medical events that jeopardize the patient or subject and may require medical or surgical intervention to prevent one of the previous outcomes mentioned.",
                            "OutcomeMeasurePopulationDescription": "1/2 participants were analyzed because one participant was taken off study per Principal Investigator discretion and did not receive drug.",
                            "OutcomeMeasureReportingStatus": "Posted",
                            "OutcomeMeasureParamType": "Count of Participants",
                            "OutcomeMeasureUnitOfMeasure": "Participants",
                            "OutcomeMeasureTimeFrame": "Date treatment consent signed to date off study, and up to 30 days following the last dose of study drug, approximately 5 months and 25 days.",
                            "OutcomeGroupList": {
                                "OutcomeGroup": [
                                    {
                                        "OutcomeGroupId": "OG000",
                                        "OutcomeGroupTitle": "ECI301 Dose Level 1 - 25 ug/kg and Radiation for Advanced or Metastatic Cancer",
                                        "OutcomeGroupDescription": "ECI301 Dose level 1 - 25 ug/kg and radiation therapy for advanced or metastatic cancer."
                                    }
                                ]
                            },
                            "OutcomeDenomList": {
                                "OutcomeDenom": [
                                    {
                                        "OutcomeDenomUnits": "Participants",
                                        "OutcomeDenomCountList": {
                                            "OutcomeDenomCount": [
                                                {
                                                    "OutcomeDenomCountGroupId": "OG000",
                                                    "OutcomeDenomCountValue": "1"
                                                }
                                            ]
                                        }
                                    }
                                ]
                            },
                            "OutcomeClassList": {
                                "OutcomeClass": [
                                    {
                                        "OutcomeCategoryList": {
                                            "OutcomeCategory": [
                                                {
                                                    "OutcomeMeasurementList": {
                                                        "OutcomeMeasurement": [
                                                            {
                                                                "OutcomeMeasurementGroupId": "OG000",
                                                                "OutcomeMeasurementValue": "1"
                                                            }
                                                        ]
                                                    }
                                                }
                                            ]
                                        }
                                    }
                                ]
                            }
                        },
                        {
                            "OutcomeMeasureType": "Other Pre-specified",
                            "OutcomeMeasureTitle": "Number of Participants With a Dose-Limiting Toxicity (DLT)",
                            "OutcomeMeasureDescription": "Examples of DLT is any grade 3 or greater non-hematologic toxicity, any grade 3 neutropenia or thrombocytopenia, any grade 4 anemia; nausea, vomiting, diarrhea, tumor pain, or pre-existing hyponatremia, dyselectrolytemia, or orthostatic hypotension that has been optimally treated with anti-emetics, anti-diarrheal, analgesics, or hydration and which persists for over 48 hours despite maximal medical therapy, and toxicity requiring a cumulative radiation treatment delay of 4 or more days.",
                            "OutcomeMeasurePopulationDescription": "1/2 participants was analyzed because one participant was taken off study per Principal Investigator discretion and did not receive drug.",
                            "OutcomeMeasureReportingStatus": "Posted",
                            "OutcomeMeasureParamType": "Count of Participants",
                            "OutcomeMeasureUnitOfMeasure": "Participants",
                            "OutcomeMeasureTimeFrame": "During treatment or the first three weeks after treatment",
                            "OutcomeGroupList": {
                                "OutcomeGroup": [
                                    {
                                        "OutcomeGroupId": "OG000",
                                        "OutcomeGroupTitle": "ECI301 Dose Level 1 - 25 ug/kg and Radiation for Advanced or Metastatic Cancer",
                                        "OutcomeGroupDescription": "ECI301 Dose level 1 - 25 ug/kg and radiation therapy for advanced or metastatic cancer."
                                    }
                                ]
                            },
                            "OutcomeDenomList": {
                                "OutcomeDenom": [
                                    {
                                        "OutcomeDenomUnits": "Participants",
                                        "OutcomeDenomCountList": {
                                            "OutcomeDenomCount": [
                                                {
                                                    "OutcomeDenomCountGroupId": "OG000",
                                                    "OutcomeDenomCountValue": "1"
                                                }
                                            ]
                                        }
                                    }
                                ]
                            },
                            "OutcomeClassList": {
                                "OutcomeClass": [
                                    {
                                        "OutcomeCategoryList": {
                                            "OutcomeCategory": [
                                                {
                                                    "OutcomeMeasurementList": {
                                                        "OutcomeMeasurement": [
                                                            {
                                                                "OutcomeMeasurementGroupId": "OG000",
                                                                "OutcomeMeasurementValue": "0"
                                                            }
                                                        ]
                                                    }
                                                }
                                            ]
                                        }
                                    }
                                ]
                            }
                        }
                    ]
                }
            },
            "AdverseEventsModule": {
                "EventsFrequencyThreshold": "0",
                "EventsTimeFrame": "Date treatment consent signed to date off study, and up to 30 days following the last dose of study drug, approximately 5 months and 25 days.",
                "EventsDescription": "1/2 participants were analyzed because one participant was taken off study per Principal Investigator discretion and did not receive drug.",
                "EventGroupList": {
                    "EventGroup": [
                        {
                            "EventGroupId": "EG000",
                            "EventGroupTitle": "ECI301 Dose Level 1 - 25 ug/kg and Radiation for Advanced or Metastatic Cancer",
                            "EventGroupDescription": "ECI301 Dose level 1 - 25 ug/kg and Radiation for Advanced or Metastatic Cancer\n\nRadiation Therapy\n\nECI301",
                            "EventGroupDeathsNumAffected": "0",
                            "EventGroupDeathsNumAtRisk": "1",
                            "EventGroupSeriousNumAffected": "0",
                            "EventGroupSeriousNumAtRisk": "1",
                            "EventGroupOtherNumAffected": "1",
                            "EventGroupOtherNumAtRisk": "1"
                        }
                    ]
                },
                "OtherEventList": {
                    "OtherEvent": [
                        {
                            "OtherEventTerm": "Alanine aminotransferase increased",
                            "OtherEventOrganSystem": "Investigations",
                            "OtherEventSourceVocabulary": "CTCAE (4.0)",
                            "OtherEventAssessmentType": "Systematic Assessment",
                            "OtherEventStatsList": {
                                "OtherEventStats": [
                                    {
                                        "OtherEventStatsGroupId": "EG000",
                                        "OtherEventStatsNumEvents": "1",
                                        "OtherEventStatsNumAffected": "1",
                                        "OtherEventStatsNumAtRisk": "1"
                                    }
                                ]
                            }
                        },
                        {
                            "OtherEventTerm": "Anemia",
                            "OtherEventOrganSystem": "Blood and lymphatic system disorders",
                            "OtherEventSourceVocabulary": "CTCAE (4.0)",
                            "OtherEventAssessmentType": "Systematic Assessment",
                            "OtherEventStatsList": {
                                "OtherEventStats": [
                                    {
                                        "OtherEventStatsGroupId": "EG000",
                                        "OtherEventStatsNumEvents": "4",
                                        "OtherEventStatsNumAffected": "1",
                                        "OtherEventStatsNumAtRisk": "1"
                                    }
                                ]
                            }
                        },
                        {
                            "OtherEventTerm": "Aspartate aminotransferase increased",
                            "OtherEventOrganSystem": "Investigations",
                            "OtherEventSourceVocabulary": "CTCAE (4.0)",
                            "OtherEventAssessmentType": "Systematic Assessment",
                            "OtherEventStatsList": {
                                "OtherEventStats": [
                                    {
                                        "OtherEventStatsGroupId": "EG000",
                                        "OtherEventStatsNumEvents": "1",
                                        "OtherEventStatsNumAffected": "1",
                                        "OtherEventStatsNumAtRisk": "1"
                                    }
                                ]
                            }
                        },
                        {
                            "OtherEventTerm": "Edema limbs",
                            "OtherEventOrganSystem": "General disorders",
                            "OtherEventSourceVocabulary": "CTCAE (4.0)",
                            "OtherEventAssessmentType": "Systematic Assessment",
                            "OtherEventStatsList": {
                                "OtherEventStats": [
                                    {
                                        "OtherEventStatsGroupId": "EG000",
                                        "OtherEventStatsNumEvents": "1",
                                        "OtherEventStatsNumAffected": "1",
                                        "OtherEventStatsNumAtRisk": "1"
                                    }
                                ]
                            }
                        },
                        {
                            "OtherEventTerm": "Erythema multiforme",
                            "OtherEventOrganSystem": "Skin and subcutaneous tissue disorders",
                            "OtherEventSourceVocabulary": "CTCAE (4.0)",
                            "OtherEventAssessmentType": "Systematic Assessment",
                            "OtherEventStatsList": {
                                "OtherEventStats": [
                                    {
                                        "OtherEventStatsGroupId": "EG000",
                                        "OtherEventStatsNumEvents": "1",
                                        "OtherEventStatsNumAffected": "1",
                                        "OtherEventStatsNumAtRisk": "1"
                                    }
                                ]
                            }
                        },
                        {
                            "OtherEventTerm": "Gastritis",
                            "OtherEventOrganSystem": "Gastrointestinal disorders",
                            "OtherEventSourceVocabulary": "CTCAE (4.0)",
                            "OtherEventAssessmentType": "Systematic Assessment",
                            "OtherEventStatsList": {
                                "OtherEventStats": [
                                    {
                                        "OtherEventStatsGroupId": "EG000",
                                        "OtherEventStatsNumEvents": "1",
                                        "OtherEventStatsNumAffected": "1",
                                        "OtherEventStatsNumAtRisk": "1"
                                    }
                                ]
                            }
                        },
                        {
                            "OtherEventTerm": "Headache",
                            "OtherEventOrganSystem": "Nervous system disorders",
                            "OtherEventSourceVocabulary": "CTCAE (4.0)",
                            "OtherEventAssessmentType": "Systematic Assessment",
                            "OtherEventStatsList": {
                                "OtherEventStats": [
                                    {
                                        "OtherEventStatsGroupId": "EG000",
                                        "OtherEventStatsNumEvents": "1",
                                        "OtherEventStatsNumAffected": "1",
                                        "OtherEventStatsNumAtRisk": "1"
                                    }
                                ]
                            }
                        },
                        {
                            "OtherEventTerm": "Hyperkalemia",
                            "OtherEventOrganSystem": "Metabolism and nutrition disorders",
                            "OtherEventSourceVocabulary": "CTCAE (4.0)",
                            "OtherEventAssessmentType": "Systematic Assessment",
                            "OtherEventStatsList": {
                                "OtherEventStats": [
                                    {
                                        "OtherEventStatsGroupId": "EG000",
                                        "OtherEventStatsNumEvents": "1",
                                        "OtherEventStatsNumAffected": "1",
                                        "OtherEventStatsNumAtRisk": "1"
                                    }
                                ]
                            }
                        },
                        {
                            "OtherEventTerm": "Lymphocyte count decreased",
                            "OtherEventOrganSystem": "Investigations",
                            "OtherEventSourceVocabulary": "CTCAE (4.0)",
                            "OtherEventAssessmentType": "Systematic Assessment",
                            "OtherEventStatsList": {
                                "OtherEventStats": [
                                    {
                                        "OtherEventStatsGroupId": "EG000",
                                        "OtherEventStatsNumEvents": "1",
                                        "OtherEventStatsNumAffected": "1",
                                        "OtherEventStatsNumAtRisk": "1"
                                    }
                                ]
                            }
                        },
                        {
                            "OtherEventTerm": "Pain in extremity",
                            "OtherEventOrganSystem": "Musculoskeletal and connective tissue disorders",
                            "OtherEventSourceVocabulary": "CTCAE (4.0)",
                            "OtherEventAssessmentType": "Systematic Assessment",
                            "OtherEventStatsList": {
                                "OtherEventStats": [
                                    {
                                        "OtherEventStatsGroupId": "EG000",
                                        "OtherEventStatsNumEvents": "1",
                                        "OtherEventStatsNumAffected": "1",
                                        "OtherEventStatsNumAtRisk": "1"
                                    }
                                ]
                            }
                        },
                        {
                            "OtherEventTerm": "Urinary tract infection",
                            "OtherEventOrganSystem": "Infections and infestations",
                            "OtherEventSourceVocabulary": "CTCAE (4.0)",
                            "OtherEventAssessmentType": "Systematic Assessment",
                            "OtherEventStatsList": {
                                "OtherEventStats": [
                                    {
                                        "OtherEventStatsGroupId": "EG000",
                                        "OtherEventStatsNumEvents": "1",
                                        "OtherEventStatsNumAffected": "1",
                                        "OtherEventStatsNumAtRisk": "1"
                                    }
                                ]
                            }
                        }
                    ]
                }
            },
            "MoreInfoModule": {
                "CertainAgreement": {
                    "AgreementPISponsorEmployee": "No",
                    "AgreementRestrictiveAgreement": "No"
                },
                "PointOfContact": {
                    "PointOfContactTitle": "Dr. Deborah E. Citrin",
                    "PointOfContactOrganization": "National Cancer Institute",
                    "PointOfContactEMail": "citrind@mail.nih.gov",
                    "PointOfContactPhone": "301-496-5457"
                }
            }
        },
        "DocumentSection": {
            "LargeDocumentModule": {
                "LargeDocList": {
                    "LargeDoc": [
                        {
                            "LargeDocTypeAbbrev": "Prot_SAP",
                            "LargeDocHasProtocol": "Yes",
                            "LargeDocHasSAP": "Yes",
                            "LargeDocHasICF": "No",
                            "LargeDocLabel": "Study Protocol and Statistical Analysis Plan",
                            "LargeDocDate": "November 1, 2011",
                            "LargeDocUploadDate": "10/29/2021 12:38",
                            "LargeDocFilename": "Prot_SAP_000.pdf"
                        },
                        {
                            "LargeDocTypeAbbrev": "ICF",
                            "LargeDocHasProtocol": "No",
                            "LargeDocHasSAP": "No",
                            "LargeDocHasICF": "Yes",
                            "LargeDocLabel": "Informed Consent Form",
                            "LargeDocDate": "November 15, 2011",
                            "LargeDocUploadDate": "10/29/2021 12:39",
                            "LargeDocFilename": "ICF_001.pdf"
                        }
                    ]
                }
            }
        },
        "DerivedSection": {
            "MiscInfoModule": {
                "VersionHolder": "September 08, 2023"
            },
            "ConditionBrowseModule": {
                "ConditionMeshList": {
                    "ConditionMesh": [
                        {
                            "ConditionMeshId": "D000009369",
                            "ConditionMeshTerm": "Neoplasms"
                        },
                        {
                            "ConditionMeshId": "D000009362",
                            "ConditionMeshTerm": "Neoplasm Metastasis"
                        },
                        {
                            "ConditionMeshId": "D000016609",
                            "ConditionMeshTerm": "Neoplasms, Second Primary"
                        }
                    ]
                },
                "ConditionAncestorList": {
                    "ConditionAncestor": [
                        {
                            "ConditionAncestorId": "D000009385",
                            "ConditionAncestorTerm": "Neoplastic Processes"
                        },
                        {
                            "ConditionAncestorId": "D000010335",
                            "ConditionAncestorTerm": "Pathologic Processes"
                        }
                    ]
                },
                "ConditionBrowseLeafList": {
                    "ConditionBrowseLeaf": [
                        {
                            "ConditionBrowseLeafId": "M11997",
                            "ConditionBrowseLeafName": "Neoplasm Metastasis",
                            "ConditionBrowseLeafAsFound": "Metastases",
                            "ConditionBrowseLeafRelevance": "high"
                        },
                        {
                            "ConditionBrowseLeafId": "M18679",
                            "ConditionBrowseLeafName": "Neoplasms, Second Primary",
                            "ConditionBrowseLeafAsFound": "Metastases",
                            "ConditionBrowseLeafRelevance": "high"
                        },
                        {
                            "ConditionBrowseLeafId": "M12020",
                            "ConditionBrowseLeafName": "Neoplastic Processes",
                            "ConditionBrowseLeafRelevance": "low"
                        }
                    ]
                },
                "ConditionBrowseBranchList": {
                    "ConditionBrowseBranch": [
                        {
                            "ConditionBrowseBranchAbbrev": "BC04",
                            "ConditionBrowseBranchName": "Neoplasms"
                        },
                        {
                            "ConditionBrowseBranchAbbrev": "BC23",
                            "ConditionBrowseBranchName": "Symptoms and General Pathology"
                        },
                        {
                            "ConditionBrowseBranchAbbrev": "All",
                            "ConditionBrowseBranchName": "All Conditions"
                        }
                    ]
                }
            }
        }
    }
}